Los Angeles Capital Management
SYRE icon

Los Angeles Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Los Angeles Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Sell
2,310
-3,548
-61% -$259K ﹤0.01% 1167
2026
Q1 		$295K Sell
5,858
-7,024
-55% -$265K ﹤0.01% 1028
2025
Q4 		$313K Sell
12,882
-5,290
-29% -$138K ﹤0.01% 1078
2025
Q3 		$305K Buy
+18,172
New +$296K ﹤0.01% 1121

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Los Angeles Capital Management's SYRE Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Spyre Therapeutics (SYRE) stake by 61% in Q2 2026, selling an estimated $259K and leaving 2,310 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

Los Angeles Capital Management first reported a position in SYRE in Q3 2025 and has held it in 4 quarters since. The position peaked at $313K in Q4 2025. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Los Angeles Capital Management held 2,310 shares of Spyre Therapeutics worth $205K as of Q2 2026.
  • Los Angeles Capital Management sold 3,548 Spyre Therapeutics shares in Q2 2026, an estimated $259K.
  • Spyre Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1167 holding.
  • Los Angeles Capital Management first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Los Angeles Capital Management's Spyre Therapeutics position peaked at $313K in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.